



Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

SAN DIEGO--(BUSINESS WIRE)--Apr. 1, 2024-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time.

The conference will be held virtually. A live webcast of Acadia's fireside chat will be accessible on the company's website, [Acadia.com](https://www.acadia.com), under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at [Acadia.com](https://www.acadia.com) and follow us on [LinkedIn](https://www.linkedin.com/company/acadia-pharm) and [Twitter](https://twitter.com/acadia_pharm).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240401383295/en/): <https://www.businesswire.com/news/home/20240401383295/en/>

Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.